BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 26044547)

  • 1. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
    Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
    Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
    Ahn KH; Mahmoud MM; Kendall DA
    J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
    McCollum L; Howlett AC; Mukhopadhyay S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.
    Shore DM; Baillie GL; Hurst DH; Navas F; Seltzman HH; Marcu JP; Abood ME; Ross RA; Reggio PH
    J Biol Chem; 2014 Feb; 289(9):5828-45. PubMed ID: 24366865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
    Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
    Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.
    Duncan M; Kendall DA; Ralevic V
    J Pharmacol Exp Ther; 2004 Oct; 311(1):411-9. PubMed ID: 15205450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
    Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
    Ihenetu K; Molleman A; Parsons M; Whelan C
    Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
    Liu Q; Bhat M; Bowen WD; Cheng J
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
    Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
    Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
    Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model.
    Green HM; Yang L; Zhu X; Finlay DB; Duffull SB; Glass M
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5105-5118. PubMed ID: 38227196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of the cannabinoid CB1 receptor.
    Price MR; Baillie GL; Thomas A; Stevenson LA; Easson M; Goodwin R; McLean A; McIntosh L; Goodwin G; Walker G; Westwood P; Marrs J; Thomson F; Cowley P; Christopoulos A; Pertwee RG; Ross RA
    Mol Pharmacol; 2005 Nov; 68(5):1484-95. PubMed ID: 16113085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
    Baillie GL; Horswill JG; Anavi-Goffer S; Reggio PH; Bolognini D; Abood ME; McAllister S; Strange PG; Stephens GJ; Pertwee RG; Ross RA
    Mol Pharmacol; 2013 Feb; 83(2):322-38. PubMed ID: 23160940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
    Järbe TU; LeMay BJ; Halikhedkar A; Wood J; Vadivel SK; Zvonok A; Makriyannis A
    Psychopharmacology (Berl); 2014 Feb; 231(3):489-500. PubMed ID: 24005529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
    Araya KA; David Pessoa Mahana C; González LG
    Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.